Integra LifeSciences Holdings Corp.

Solventum has entered into an agreement to acquire Acera Surgical, a developer of materials for regenerative wound care, for $850 million. The deal will include an upfront cash payment of $725 million, followed by a $125 million contingent cash payment based on strong performance. Since 2013, Acera has specialized in developing and commercializing synthetic treatment options for soft tissue repair using its proprietary electrospinning technology platform. The company’s flagship Restrata products are widely used in the U.S. market for treating hard-to-heal, complex wounds in acute care settings. The acquisition will position Solventum as a strong player in the regenerative tissue matrices category within the acute care settings market, which is estimated to be worth $900 million. The partnership is expected to boost the adoption of Restrata products in the acute care market by leveraging Solventum's global footprint, specialized wound care sales force, and leadership in negative pressure wound therapy. In 2025, Acera is predicted to generate $90 million in sales. The partnership deal will likely close in the first half of 2026, subject to customary closing conditions. “Regenerative wound care is an exciting and fast-growing space, and Acera has innovative technology to meet a significant unmet need in acute wound care," Bryan Hanson, chief executive officer of Solventum, said in a prepared statement. "Expanding our advanced wound care portfolio into the high-growth synthetic tissue matrices category complements solutions within our existing portfolio and enhances the options our specialized commercial team can provide doctors, nurses, and decision makers within acute care settings.” This acquisition did not come as a surprise to several industry experts, according to a BTIG analyst report. Solventum has been leaning into the wound management space for quite some time, and this new deal will give it a leg up in the market. “We like this transaction for SOLV. We think it keeps SOLV's focus on the inpatient setting complementing their existing portfolio in synthetic grafts and provides a high-growth contributor to the portfolio driving top-line growth in FY26 and beyond. If there is any specific read-through on other names, it would be negative for Integra LifeSciences, who competes in this inpatient segment primarily,” one BTIG analyst wrote. Though the acquisition is favorable, BTIG remains neutral on Solventum for the remainder of 2025. The company, which just launched as an independent healthcare business in April 2024 after spinning off from 3M Healthcare, has had a strong year financially. In August, MD+DI editors identified it as possibly being the medtech industry’s strongest and most successful spin-off to date. In the second quarter of 2025, Solventum exceeded financial expectations with revenue of $2.16 billion and earnings per share of $1.69—surpassing analyst consensus estimates of $2.1 billion and $1.45, respectively. In addition, the company reduced its tariff impact down to $60 million to $80 million as opposed to the prior expectation of $80 million to $100 million. Despite strong financials, BTIG remains neutral on the company’s stock following a lack of investor interest. “SOLV's share underperformance post-spin is evidence of investors' lack of enthusiasm for SOLV shares today. Between a hodgepodge of market segments with limited overlap, limited growth collectively, rising operating costs post-spin, and lack of margin expansion, SOLV has a lot of 'wood to chop' before it can win investors over. In our view, the playbook to create value is clear but the timelines to get there could be long,” analysts wrote.

Neurosurgery device specialist Integra LifeSciences has posted its financial results for the third quarter of 2025, with revenues growing 5.6% on a reported basis and 5% on an organic basis compared to the prior year. The company’s quarterly earnings of $0.54 per share beat several analysts' predictions, rising from $0.41 per share a year ago. The devicemaker expected to post earnings of $0.43 per share. In three of the last four quarters, Integra surpassed consensus EPS estimates. The company posted revenues of $402.06 million for the quarter that ended September 2025. Despite strong quarterly earnings results, throughout 2025, Integra has consistently underperformed in the market. For that reason, analyst BTIG has reiterated its “neutral” stance on the company, even following a strong third quarter. Integra also lowered its full year guidance for 2025 to $1.620B - $1.640B, as it saw a drop in organic revenue. “All of this should not come as too much of a surprise given IART's operational history. We think there are emerging positive signs in terms of quality remediation and improving supply chain dynamics such as early product relaunches and the Braintree, MA facility reopening on time but early FY26 commentary continues to point to modest growth expectations,” BTIG analysts wrote. “Given IART's track record, it's best to remain on the sidelines.” The company has yet to provide full 2026 guidance, but it expects to see modest revenue growth, according to early statements. While IART is the global leader in neurosurgery through its CSS segment, and is one of the largest players in regenerative medicine through its Tissue Technologies segment, nagging supply chain, quality, and regulatory challenges have harmed its growth and shares are sitting at an all-time-low. During the quarter, the company did relaunch its PriMatrix and Durepair devices ahead of schedule through a dual sourcing supply strategy, and it appointed Dr. Raymond Turner, a board-certified neurosurgeon and fellowship-trained in endovascular neurosurgery, as chief medical officer. Analysts also remained neutral on Integra following its Q2 financial results, with MD+DI rating the company as a “draw” in August. Integra also lowered its full-year guidance in 2024 after struggling with quality control issues.

BERKELEY, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Channel Medsystems, Inc., a privately held company dedicated to advancing women’s health with innovative solutions, announced today the appointment of Skip Baldino to its Board of Directors. Mr. Baldino brings more than 35 years of executive leadership in both private start-ups and large public healthcare companies to this role, with a proven track record of leading organizations through significant growth, commercial expansion, and strategic transformation. He most recently served as President and Chief Executive Officer of Gynesonics, a women’s health company focused on minimally invasive solutions for uterine conditions. During his tenure, he led the global commercialization of the Sonata® Treatment System and positioned the company for successful acquisition by Hologic in 2025. Prior to that, Mr. Baldino held senior leadership roles at Abbott Laboratories, Given Imaging, and EndoGastric Solutions. He has also served as Chairman of the Board at ACell prior to their acquisition by Integra. “Skip’s expertise in commercial strategy, operations, and healthcare innovation makes him an invaluable addition to our Board,” said Nelson Whistance, President and Chief Executive Officer of Channel Medsystems. “His insights will be instrumental as we accelerate adoption of our Cerene® Cryotherapy Device and continue advancing our mission to deliver safe, effective, and accessible treatment options for women.” Mr. Baldino’s appointment comes at a pivotal time for Channel Medsystems, as the company builds commercial momentum and expands access to the Cerene Cryotherapy Device—a modern, incision-free treatment for women with heavy menstrual bleeding (HMB) and dysmenorrhea. Cerene is non-hormonal, requires no general anesthesia, can be performed in any site of service, and can provide lasting relief from heavy bleeding and painful periods, helping women return to normal life with greater comfort and control. “I am honored to join the Channel Medsystems Board at such an exciting stage in the company’s journey,” said Baldino. “Channel’s focus on advancing women’s health through cryotherapy innovation aligns perfectly with my own commitment to improving care and outcomes. I look forward to collaborating with the team to accelerate growth and impact.” With Baldino’s appointment, Channel Medsystems strengthens its Board with seasoned leadership to help guide the company’s next phase of expansion and long-term success. About Channel MedsystemsChannel Medsystems is a privately held company dedicated to transforming women’s healthcare globally through the development and commercialization of its flagship product, the Cerene® Cryotherapy Device. Cerene is a non-hormonal, incision-free treatment designed to provide safe, effective, and convenient therapy for women suffering from heavy menstrual bleeding (HMB) and dysmenorrhea. Offering a modern alternative to invasive surgery or long-term medications, Channel Medsystems is committed to improving patient outcomes, broadening access, and empowering women with greater control over their care. For more information, please visit www.cerene.com. Media Contact:Tara MurphyVice President, MarketingChannel Medsystemstmurphy@cerene.com 215-620-3004